Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR‐Mutant NSCLC

Lignende værker

• Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
  af: Margaret Stalker, MD, et al.
  Udgivet: (2025-01-01)
• Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
  af: Nathaniel J. Myall, MD, et al.
  Udgivet: (2025-02-01)
• The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
  af: Ikei S. Kobayashi, MD, PhD, et al.
  Udgivet: (2024-01-01)
• Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
  af: Jie Wang, MD, PhD, et al.
  Udgivet: (2024-02-01)
• Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC
  af: Shinkichi Takamori, MD, PhD, et al.
  Udgivet: (2026-04-01)